Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRIGrowth Rate was 43.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 30.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 13.00% per year.
During the past 13 years, PCI Biotech Holding ASA's highest 3-Year average EPS without NRI Growth Rate was 43.00% per year. The lowest was -44.50% per year. And the median was -0.25% per year.
PCI Biotech Holding ASA (OSL:PCIB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
PCI Biotech Holding ASA Earnings per Share (Diluted) Related Terms
PCI Biotech Holding ASA Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for PCI Biotech Holding ASA's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA Earnings per Share (Diluted) Chart
OSL:PCIB vs VRTX, REGN, ALNY: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, PCI Biotech Holding ASA's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's PE Ratio distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's PE Ratio falls into.
PCI Biotech Holding ASA Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
PCI Biotech Holding ASA's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr-0.55 mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Earnings per Share (Diluted) of kr-0.55 as of Jun. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Earnings per Share (Diluted) too high?
PCI Biotech Holding ASA's current Earnings per Share (Diluted) is kr-0.55. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Earnings per Share (Diluted) compare to VRTX and REGN?
PCI Biotech Holding ASA's Earnings per Share (Diluted) of kr-0.55 can be compared against companies in the Biotechnology industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current Earnings per Share (Diluted) is kr-0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Earnings per Share (Diluted) of kr-0.55. The current Earnings per Share (Diluted) is kr-0.55. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Earnings per Share (Diluted) is kr-0.55 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
